Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece.
Las Vegas, NV, January 03, 2008 --(PR.com)-- Amphocil Successfully Launched in Greece
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece.
Amphocil (amphotericin B cholesteryl sulfate), an injection, is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.
Dr. Janet Greeson of Samaritan stated, "We are making great strides in making Samaritan a revenue company. The niche territories of Greece and Eastern Europe are often overlooked although together the territories account for 300 million people so we see it as an opportunity. Getting an already approved U.S. or European drug launched in our targeted territories takes a special expertise and long term relationships. We are fortunate to have built relationships in Ireland through Pharmaplaz, Ireland and we are extremely fortunate to have Dr. Christos Dakas as our European Director, who has built a long list of credible relationships in Greece and Eastern Europe. We give Dr. Dakas and Eugene Boyle a lot of credit for their persistence in trying to make Samaritan self sustaining in the future.''
Visit List of In-licensed Products: http://www.samaritanpharma.com/marketed_products.asp
Visit Product Website: http://www.amphocil.com
Three Rivers Pharmaceuticals(r):
Established in 2000, Three Rivers Pharmaceuticals devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies, which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of antiviral and antifungal agents. The company has continued to expand its product line into the branded market with the acquisition of AMPHOTEC(r)/AMPHOCIL(r) in May of 2005. This product is currently being marketed in over 40 countries worldwide.
Samaritan Pharmaceuticals:
"Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
###
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece.
Amphocil (amphotericin B cholesteryl sulfate), an injection, is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.
Dr. Janet Greeson of Samaritan stated, "We are making great strides in making Samaritan a revenue company. The niche territories of Greece and Eastern Europe are often overlooked although together the territories account for 300 million people so we see it as an opportunity. Getting an already approved U.S. or European drug launched in our targeted territories takes a special expertise and long term relationships. We are fortunate to have built relationships in Ireland through Pharmaplaz, Ireland and we are extremely fortunate to have Dr. Christos Dakas as our European Director, who has built a long list of credible relationships in Greece and Eastern Europe. We give Dr. Dakas and Eugene Boyle a lot of credit for their persistence in trying to make Samaritan self sustaining in the future.''
Visit List of In-licensed Products: http://www.samaritanpharma.com/marketed_products.asp
Visit Product Website: http://www.amphocil.com
Three Rivers Pharmaceuticals(r):
Established in 2000, Three Rivers Pharmaceuticals devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies, which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of antiviral and antifungal agents. The company has continued to expand its product line into the branded market with the acquisition of AMPHOTEC(r)/AMPHOCIL(r) in May of 2005. This product is currently being marketed in over 40 countries worldwide.
Samaritan Pharmaceuticals:
"Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
###
Contact
Samaritan Pharmaceuticals
Tom Vosicky
702-735-7001
www.samaritanpharma.com
Tom Vosicky
702-735-7001
www.samaritanpharma.com
Contact
Categories